ライフサイエンスコーパス: hypereosinophilic syndrome

1 nologic conditions, and various forms of the hypereosinophilic syndrome.

2 atory diseases including allergic asthma and hypereosinophilic syndrome.

3 ive as a corticosteroid-sparing agent in the hypereosinophilic syndrome.

4 with no increase in clinical activity of the hypereosinophilic syndrome.

5 antibody, mepolizumab, in patients with the hypereosinophilic syndrome.

6 ents negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome.

7 d thrombotic diathesis characteristic of the hypereosinophilic syndrome.

8 eosinophilia-myalgia syndrome and idiopathic hypereosinophilic syndrome.

9 n eosinophilic leukemia and the 'idiopathic' hypereosinophilic syndromes.

10 eosinophilic leukemia and in the idiopathic hypereosinophilic syndrome also have been further define

11 ively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 conc

12 eceptor alpha (PDGFRalpha) as a cause of the hypereosinophilic syndrome and of chronic eosinophilic l

13 DGFRalpha fusion kinase in about half of the hypereosinophilic syndrome cases.

14 The contemporary definition of the hypereosinophilic syndromes encompasses a range of eosin

15 For example, patients with the hypereosinophilic syndrome have received mepolizumab, an

16 reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia

17 ity in identifying a subset of patients with hypereosinophilic syndrome (HES) and an underlying myelo

18 Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophili

19 None (0%) of 57 patients with the hypereosinophilic syndrome (HES) but 10 (56%) of 19 pati

20 Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative

21 Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative

22 In 2012, idiopathic hypereosinophilic syndrome (HES) is still the prevalent

23 Four patients with hypereosinophilic syndrome (HES) refractory to or intole

24 Hypereosinophilic syndrome (HES) represents a group of i

25 cytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastoc

26 ene has been identified as a cause of clonal hypereosinophilic syndrome (HES), called F/P-positive ch

27 (SM) and chronic eosinophilic leukemia (CEL)/hypereosinophilic syndrome (HES).

28 s of imatinib response in clinically-defined hypereosinophilic syndrome (HES).

29 nule proteins were lower than in nonfamilial hypereosinophilic syndrome (HES).

30 therapeutic target for imatinib mesylate in hypereosinophilic syndrome (HES).

31 Although most patients with hypereosinophilic syndromes (HES) present with clinical

32 In 1968, the term hypereosinophilic syndromes (HES) was coined to refer to

33 Hypereosinophilic syndromes (HESs) are a diverse group o

34 Hypereosinophilic syndromes (HESs) are a group of rare d

35 Hypereosinophilic syndromes (HESs) are a heterogeneous g

36 Hypereosinophilic syndromes (HESs) are chronic disorders

37 Hypereosinophilic syndromes (HESs) are disorders charact

38 ondary causes of eosinophilia, an idiopathic hypereosinophilic syndrome (I-HES) was diagnosed.

39 esulting in the development of an idiopathic hypereosinophilic syndrome (IHES) with eosinophilic derm

40 A hypereosinophilic syndrome in patients after liver trans

41 asthma, allergic and parasitic diseases, and hypereosinophilic syndromes, in addition to more recentl

42 tail the diagnosis and management of various hypereosinophilic syndromes including the clonal eosinop

43 As our understanding of the various hypereosinophilic syndromes increases, and we are able t

44 Idiopathic hypereosinophilic syndrome involves a prolonged state of

45 The hypereosinophilic syndrome is a group of diseases charac

46 Hypereosinophilic syndrome is a heterogeneous group of r

47 The idiopathic hypereosinophilic syndrome is a rare hematologic disorde

48 very of the FIP1L1-PDGFRA fusion gene in the hypereosinophilic syndrome is an example of the power of

49 or patients in whom no underlying disease or hypereosinophilic syndrome is found, the term hypereosin

50 The hypereosinophilic syndrome may result from a novel fusio

51 pression was decided in four patients due to hypereosinophilic syndrome, parvovirus infection, aspira

52 ch cause chronic myelomonocytic leukemia and hypereosinophilic syndrome, respectively.

53 Patients with hypereosinophilic syndrome show persistent eosinophilia

54 Ulcerated lesions from patients with the hypereosinophilic syndrome showed ECP and EDN deposition

55 Although studied in idiopathic hypereosinophilic syndrome, the therapeutic niche of ant

56 humans and dysregulated in individuals with hypereosinophilic syndrome, this long non-coding RNA may

57 We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified

58 ssful empiric treatment of patients with the hypereosinophilic syndrome with the selective tyrosine k

59 These may also prove useful for other hypereosinophilic syndromes without PDGFRA or PDGFRB rea